Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Seattle Genetics brentuximab vedotin, dacetuzumab clinical data to be presented at ICML 2011

Seattle Genetics, Inc. today announced that data from its brentuximab vedotin and dacetuzumab programs will be presented at the 11th International Conference on Malignant Lymphoma being held June 15-18, 2011 in Lugano, Switzerland.

16 Jun 2011

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

InNexus Biotechnology Inc., a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announced today that it has filed for patent protection covering a novel antibody product for Age-related Macular Degeneration (AMD) and other eye disorders.

16 Jun 2011

Cambridge Biomedical, Neogenix partner to develop ELISA assays for pancreatic and colorectal cancer

Neogenix Oncology, Inc. is pleased to announce it has signed an agreement with Cambridge Biomedical, Inc, based in Boston, MA, for the development of its pancreatic and colorectal cancer diagnostic serum ELISA assays.

16 Jun 2011

Serious RSV infections may occur in previously healthy infants and children

For most parents, respiratory syncytial virus (RSV) isn't a familiar term. But it's a common cause of serious respiratory infections with a major impact on the health of infants and young children worldwide, according to a special CDC Review Article in the June issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

16 Jun 2011

ProImmune introduces new uniquely powerful protein and peptide array platform

ProImmune Ltd., a leader in services for understanding immune responses, announced today that it has launched ProArray Ultra, a uniquely powerful protein and peptide array platform, which is more sensitive than optimized ECL ELISA.

16 Jun 2011

Novartis Bexsero pivotal study data on meningococcal serogroup B presented at ESPID

New data from a pivotal study in more than 1,800 infants show that Novartis candidate vaccine Bexsero induces a robust immune response to meningococcal serogroup B when given alone or when co-administered with other routine vaccines.

15 Jun 2011

Bayer's submission of IND for BAY 94-9343 triggers $2M milestone payment to ImmunoGen

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Bayer HealthCare Pharmaceuticals' submission of an Investigational New Drug (IND) application for the TAP compound, BAY 94-9343, triggers a $2 million milestone payment to ImmunoGen.

15 Jun 2011

Kurma, CRT launch BliNK Therapeutics to generate monoclonal antibodies

Cancer Research Technology, the commercial arm of Cancer Research UK, and Paris-based venture capital firm, Kurma Life Sciences Partners (Kurma), have launched a spin-out company, BliNK Therapeutics Ltd, to generate monoclonal antibodies using a novel platform.

13 Jun 2011

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc., announced today that data on ADCETRIS (brentuximab vedotin) in relapsed or refractory Hodgkin lymphoma patients were featured in an oral presentation at the 16th Congress of the European Hematology Association (EHA) in London.

13 Jun 2011

PharmAthene to sell $6.5M of common stock and warrants in registered direct offering

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it has entered into subscription agreements with certain institutional investors to sell approximately $6.5 million of its common stock and warrants in a registered direct offering.

10 Jun 2011

Blinatumomab phase 2 trial results on acute lymphoblastic leukemia to be presented at EHA 2011

Data to be presented tomorrow at the 16th Annual Meeting of the European Hematology Association (EHA) in London, UK, show that Micromet's blinatumomab produced a high complete remission rate in adult patients with acute lymphoblastic leukemia (ALL) who had relapsed following treatment with standard therapy.

10 Jun 2011

GeneTex to introduce new Easy-iPSC minicircle DNA vector technology in June

GeneTex, a leading manufacturer of antibodies for research use, is pleased to announce they will be launching several new exciting products in June, including the new Easy-iPSC minicircle DNA vector technology.

9 Jun 2011

PDL revises revenue guidance for second quarter 2011 to $122M

PDL BioPharma, Inc. (PDL) today revised its guidance for the second quarter ending June 30, 2011, to approximately $122 million, as compared with actual results of $120 million for the second quarter of 2010, an anticipated one percent year-over-year increase.

9 Jun 2011

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that Seattle Genetics has exercised an option to co-develop a second antibody-drug conjugate (ADC) under the companies' existing ADC collaboration agreement.

9 Jun 2011

Adjuvant combination generates memory CD8 T cells which could kill infected cells

Researchers at National Jewish Health have discovered how to prime a second arm of the immune system to potentially boost influenza vaccine effectiveness. A combination of two adjuvants, chemicals used to boost the effectiveness of some vaccines, induced CD8, or killer, T cells to join antibodies in response to influenza infection.

9 Jun 2011

Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

Merck, known as MSD outside the United States and Canada, and Intercell AG (VSE: ICLL) today announced that following a detailed analysis of the data from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infection, the independent Data Monitoring Committee (DMC) has unanimously recommended termination of the study.

8 Jun 2011

NYU Cancer Institute scientists present new research findings at ASCO 2011

Experts from The Cancer Institute, an NCI-designated cancer center, at NYU Langone Medical Center presented new research findings at the 47th American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago, IL.

8 Jun 2011

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two studies of VELCADE (bortezomib) for Injection based combinations in patients with relapsed or refractory multiple myeloma (MM).

8 Jun 2011

Quest conducts first clinical Investigators Meeting for Oregovomab in Rome, provides corporate updates

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announced today that it conducted its first clinical Investigators Meeting for Oregovomab in Rome, Italy.

8 Jun 2011

Vaccine candidate produces immune response to antigen in all strains of influenza A

A universal influenza vaccine targeting a protein common to all strains of influenza A has safely produced an immune response in humans. If proven effective, the vaccine could eliminate the practice of creating a new flu vaccine annually to match predicted strains, with major implications for global health.

8 Jun 2011

Antibody News and Research

Further Reading

Seattle Genetics brentuximab vedotin, dacetuzumab clinical data to be presented at ICML 2011

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

Cambridge Biomedical, Neogenix partner to develop ELISA assays for pancreatic and colorectal cancer

Serious RSV infections may occur in previously healthy infants and children

ProImmune introduces new uniquely powerful protein and peptide array platform

Novartis Bexsero pivotal study data on meningococcal serogroup B presented at ESPID

Bayer's submission of IND for BAY 94-9343 triggers $2M milestone payment to ImmunoGen

Kurma, CRT launch BliNK Therapeutics to generate monoclonal antibodies

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

PharmAthene to sell $6.5M of common stock and warrants in registered direct offering

Blinatumomab phase 2 trial results on acute lymphoblastic leukemia to be presented at EHA 2011

GeneTex to introduce new Easy-iPSC minicircle DNA vector technology in June

PDL revises revenue guidance for second quarter 2011 to $122M

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Adjuvant combination generates memory CD8 T cells which could kill infected cells

Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

NYU Cancer Institute scientists present new research findings at ASCO 2011

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Quest conducts first clinical Investigators Meeting for Oregovomab in Rome, provides corporate updates

Vaccine candidate produces immune response to antigen in all strains of influenza A

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo